Key Points
- Director Richard Prins sold 4,179 shares on November 25 at an average price of $27.10 for $113,250.90, reducing his stake by 10.62% to 35,183 shares.
- Amphastar beat recent quarterly expectations with $0.93 EPS versus $0.83 expected and $191.84M in revenue versus $186.90M, and analysts project about 3.49 EPS for the current fiscal year.
- Analysts have a consensus rating of Hold with an average price target of $31.20, amid mixed recent revisions (e.g., Piper Sandler lowered its target to $25 while Bank of America raised its target to $32).
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Richard Prins sold 4,179 shares of the company's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the transaction, the director owned 35,183 shares of the company's stock, valued at $953,459.30. This trade represents a 10.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Amphastar Pharmaceuticals Trading Up 3.7%
AMPH opened at $27.69 on Wednesday. The stock has a market capitalization of $1.27 billion, a P/E ratio of 10.37 and a beta of 0.77. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $46.11. The firm's fifty day simple moving average is $25.62 and its 200 day simple moving average is $25.46.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.83 by $0.10. The firm had revenue of $191.84 million during the quarter, compared to analysts' expectations of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 20.76% and a net margin of 18.64%. As a group, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current fiscal year.
Hedge Funds Weigh In On Amphastar Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in AMPH. Farther Finance Advisors LLC raised its position in Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company's stock worth $25,000 after acquiring an additional 737 shares in the last quarter. Global Retirement Partners LLC grew its position in shares of Amphastar Pharmaceuticals by 219.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company's stock valued at $27,000 after acquiring an additional 703 shares during the period. MassMutual Private Wealth & Trust FSB increased its stake in shares of Amphastar Pharmaceuticals by 192.8% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company's stock worth $29,000 after purchasing an additional 831 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 3,430.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company's stock valued at $32,000 after purchasing an additional 1,338 shares during the period. Finally, Quarry LP bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at about $32,000. 65.09% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the company. Piper Sandler dropped their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research report on Friday, August 8th. Needham & Company LLC decreased their price target on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Friday, November 7th. Weiss Ratings reissued a "hold (c)" rating on shares of Amphastar Pharmaceuticals in a research report on Monday. Zacks Research cut shares of Amphastar Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, November 14th. Finally, Bank of America lifted their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. Two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $31.20.
View Our Latest Analysis on AMPH
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
